Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
225Ac-rhPSMA-10.1
- Development stage
- Phase 2
- Lead developer
- Blue Earth Therapeutics
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
225Ac-rhPSMA-10.1 is an investigational radiohybrid (rh) Prostate-Specific Membrane Antigen (PSMA)-targeted therapeutic radiopharmaceutical designed for the treatment of prostate cancer, specifically metastatic castration-resistant prostate cancer (mCRPC). It is a next-generation alpha-emitting radioligand therapy that selectively binds to PSMA, a protein highly expressed on prostate cancer cells, delivering targeted alpha radiation via actinium-225 to induce tumor cell death while sparing surrounding healthy tissue. Preclinical studies have demonstrated high PSMA binding affinity, efficient cellular internalization, and significant tumor growth suppression in prostate cancer models at much lower radioactivity compared to beta-emitting analogs such as 177Lu-rhPSMA-10.1[4][5][6]. The drug is being developed by Blue Earth Therapeutics and has entered phase 1/2 clinical trials for mCRPC[2].
- Other names
- Actinium (225Ac) rhPSMA-10.1
02
Targets
PSMA (Prostate-specific membrane antigen)
Beyond the preview
Go deeper on 225Ac-rhPSMA-10.1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 225Ac-rhPSMA-10.1.